Universal Informatics · Research reading room

Pilot study of H2 therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trial

Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N. · Movement disorders : official journal of the Movement Disorder Society · 2013 · randomised controlled trial, double blind

Original publication · Original publication

Attributed extracts from the research record

“drinking hydrogen (H2) water for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD) patients treated with levodopa”

Evidence and provenance

Chapter Trust Factor uses a minimum of three distinct qualifying studies. Publication records retain their own evidence and assessment.

Study design and assessment
design
randomised controlled trial, double blind
assessment
Not recorded
trust Factor
score
3
scope
Paper
status
assessed
randomized Controlled Trial
true
blinding
double
peer Reviewed
true
basis
Indexed randomized trial and double-blind methods.
sources

https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375 · https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.25375

review Scope
Existing publication-specific assessments and bibliographic indexing; no blanket full-text appraisal.
assessed At
2026-10-27
jadad
status
unassessed
score
Not recorded
evidence
Not recorded
Topics and recorded topic scores
  1. key
    language:vi
    title
    Molecular hydrogen: inflammation, cognition and gene expression
    collection
    language
    trust Score
    3
  2. key
    general:language-vi
    title
    Molecular hydrogen: inflammation, cognition and gene expression
    collection
    general
    trust Score
    3
Citation snapshot and identifiers
id
pmid-23400965
doi
10.1002/mds.25375
pmid
23400965
citation Snapshot
Not recorded
citations By Collection
language
108
general
108
Complete approved library record
id
pmid-23400965
publication Key
Not recorded
aliases
None recorded
title
Pilot study of H2 therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trial
journal
Movement disorders : official journal of the Movement Disorder Society
neurotransmitters
None recorded
year
2013
authors
Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N.
design
randomised controlled trial, double blind
kind
Journal article
identity Conflict
Not recorded
doi
10.1002/mds.25375
pmid
23400965
urls

https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375

collections

language · general

categories

Methods & context

targets
None recorded
priority
1
quotes

“drinking hydrogen (H2) water for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD) patients treated with levodopa”

summary
limitation
citation Count
108
paper Trust Assessment
score
3
scope
Paper
status
assessed
randomized Controlled Trial
true
blinding
double
peer Reviewed
true
basis
Indexed randomized trial and double-blind methods.
sources

https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375 · https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.25375

review Scope
Existing publication-specific assessments and bibliographic indexing; no blanket full-text appraisal.
assessed At
2026-10-27
citations By Collection
language
108
general
108
topics
  1. key
    language:vi
    title
    Molecular hydrogen: inflammation, cognition and gene expression
    collection
    language
    trust Score
    3
  2. key
    general:language-vi
    title
    Molecular hydrogen: inflammation, cognition and gene expression
    collection
    general
    trust Score
    3
journal Key
movementdisorders
journal Label
Movement disorders : official journal of the Movement Disorder Society
chapter Entries
  1. id
    language-vi-pmid-23400965
    record Id
    pmid-23400965
    title
    Pilot study of H2 therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trial
    journal
    Movement disorders : official journal of the Movement Disorder Society
    year
    2013
    authors
    Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N.
    design
    randomised controlled trial, double blind
    urls

    https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375

    quotes
      1. text
        “drinking hydrogen (H2) water for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD) patients treated with levodopa”
        emphasis
        false
    citation Count
    108
    source Pages

    24

    targets
    None recorded
    categories

    Methods & context

    doi
    10.1002/mds.25375
    pmid
    23400965
    paper Trust Assessment
    score
    3
    scope
    Paper
    status
    assessed
    randomized Controlled Trial
    true
    blinding
    double
    peer Reviewed
    true
    basis
    Indexed randomized trial and double-blind methods.
    sources

    https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375 · https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.25375

    review Scope
    Existing publication-specific assessments and bibliographic indexing; no blanket full-text appraisal.
    assessed At
    2026-10-27
    collection
    language
    chapter Number
    1
    topic Id
    vi
    topic Title
    Molecular hydrogen: inflammation, cognition and gene expression
    trust Score
    3
  2. id
    general-language-vi-pmid-23400965
    record Id
    pmid-23400965
    title
    Pilot study of H2 therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trial
    journal
    Movement disorders : official journal of the Movement Disorder Society
    year
    2013
    authors
    Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N.
    design
    randomised controlled trial, double blind
    urls

    https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375

    quotes
      1. text
        “drinking hydrogen (H2) water for 48 weeks significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD) patients treated with levodopa”
        emphasis
        false
    citation Count
    108
    source Pages

    24

    targets
    None recorded
    categories

    Methods & context

    doi
    10.1002/mds.25375
    pmid
    23400965
    paper Trust Assessment
    score
    3
    scope
    Paper
    status
    assessed
    randomized Controlled Trial
    true
    blinding
    double
    peer Reviewed
    true
    basis
    Indexed randomized trial and double-blind methods.
    sources

    https://pubmed.ncbi.nlm.nih.gov/23400965/ · https://doi.org/10.1002/mds.25375 · https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.25375

    review Scope
    Existing publication-specific assessments and bibliographic indexing; no blanket full-text appraisal.
    assessed At
    2026-10-27
    collection
    general
    chapter Number
    3
    topic Id
    language-vi
    topic Title
    Molecular hydrogen: inflammation, cognition and gene expression
    trust Score
    3
jadad
status
unassessed
score
Not recorded
condition Evidence
None recorded
conditions
None recorded
topic Trust Scores

3

full Text
status
not-indexed
retrieval Available
false

Open this publication in the interactive library